Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.59 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845198 | 1.00 | ESR1 (0.59) | ESR1LTA4HESR2 | |
| SCHEMBL26660508 | 0.89 | LTA4H (0.51) | ESR1LTA4HESR2 | |
| SCHEMBL17845178 | 0.88 | ESR1 (0.56) | ESR1 | |
| SCHEMBL21780941 | 0.86 | HRH3 (0.56) | ESR1LTA4H | |
| SCHEMBL17845116 | 0.86 | ESR1 (0.49) | ESR1LTA4H | |
| SCHEMBL17845086 | 0.86 | ESR1 (0.49) | ESR1LTA4H | |
| SCHEMBL21780869 | 0.86 | TMEM97 (0.63) | ESR1LTA4H | |
| SCHEMBL17845172 | 0.83 | ESR1 (0.62) | ESR1ESR2 | |
| SCHEMBL21780775 | 0.83 | ESR1 (0.62) | ESR1ESR2 | |
| SCHEMBL17845169 | 0.83 | ESR1 (0.62) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-05-13 | — | — | US | disclosed |
| CN-112041307-B | Substituted benzothiophene analogs as selective estrogen receptor degrading agents | 伊利诺伊大学评议会 | 2024-02-09 | — | — | CN | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | ESR1, GPER1, CYP19A1 | ESR1 1/4885LTA4H 712/4885ESR2 5/4885 |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885LTA4H 1908/4885ESR2 1/4885 |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | ESR1, GPER1, CYP19A1 | ESR1 1/4885LTA4H 712/4885ESR2 5/4885 |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, CYP19A1 | ESR1 1/4885LTA4H 712/4885ESR2 5/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885LTA4H 1908/4885ESR2 1/4885 |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, CYP19A1 | ESR1 1/4885LTA4H 712/4885ESR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.